Bio-Rad Still Mulling Acquisition Opportunities; Q2 Revenues Rise 9 Percent on Strong Dx Sales | GenomeWeb
Bio-Rad Laboratories is still considering potential acquisition opportunities but is maintaining what its calls a “disciplined approach” in spending its cash holdings of $246 million, company officials said last week.
The firm has not been as aggressive as some of its chief competitors — namely Qiagen and Invitrogen — in the M&A market over the past couple of years, but each quarter analysts quiz company officials about the firm’s acquisition plans.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.